Mylan sues generic rival Teva over 'sophisticated scheme' to block Copaxone copycats

Teva Pharmaceutical is facing down plenty of lawsuits. Now, one of its chief rivals in the generics field is adding another case to Teva's plate.

Mylan, which has merged with Pfizer's Upjohn to form Viatris, is taking Teva to court over claims the Israeli-American drugmaker used anticompetitive practices to guard its branded multiple sclerosis med Copaxone from generics.